Related Experiment Videos
Changes in tumor hypoxia measured with a double hypoxic marker technique
A S Ljungkvist1, J Bussink, P F Rijken
1Department of Radiation Oncology, Joint Centre for Radiation Oncology Arnhem-Nijmegen, Nijmegen, The Netherlands.
International Journal of Radiation Oncology, Biology, Physics
|December 21, 2000
Summary
This study developed a novel assay using two nitroimidazole derivatives, CCI-103F and pimonidazole, to measure tumor hypoxia. The assay successfully detected significant changes in tumor oxygenation after carbogen breathing and hydralazine treatment.
Area of Science:
- Biomedical research
- Cancer biology
- Tumor microenvironment
Background:
- Tumor hypoxia is a critical factor influencing cancer progression and treatment resistance.
- Accurate measurement of tumor oxygenation is essential for developing effective cancer therapies.
Purpose of the Study:
- To develop and validate a double hypoxic cell marker assay using CCI-103F and pimonidazole.
- To investigate changes in tumor hypoxia following interventions that modify tumor oxygenation.
Main Methods:
- Utilized immunohistochemical techniques to visualize hypoxic markers CCI-103F and pimonidazole.
- Employed a human laryngeal squamous cell carcinoma xenograft model.
- Applied a semiautomatic image analysis system for quantitative measurements and double staining for qualitative analysis.
Main Results:
- Demonstrated a significant correlation between CCI-103F and pimonidazole in air-breathing animals.
- Observed a significant decrease in hypoxic fraction from 0.07 to 0.03 after carbogen breathing.
- Showed a significant increase in hypoxic fraction following hydralazine administration.
Conclusions:
- The developed double marker assay effectively quantifies changes in tumor hypoxia.
- Carbogen breathing significantly reduces tumor hypoxia, particularly near well-perfused regions.
- Hydralazine administration significantly increases tumor hypoxia.